Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Sarepta Therapeutics,, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $17.61
+7.4% in 7d after detection
Post-detection moves
1h
—
1d
+2.9%
3d
+1.0%
7d
+7.4%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS